81 results about "Pathogen inactivation" patented technology

The present invention is directed to pathogen inactivating compositions that can be used to disinfect various biological fluids, such as blood, blood fractions, and the like. The compositions are suitable for disinfecting biological fluids containing valuable, but labile, components such as proteins without destroying the desired properties of such components. The pathogen inactivating compositions of the present invention are produced by contacting water or an aqueous solution with iodinated matrix material. The compositions can be pre-formulated and stored for subsequent use in disinfecting a wide range of biological fluids.

Systems and methods process blood and blood components for subsequent pathogen inactivation processes prior to long term storage and/or transfusion.

Membranes and methods for making membranes are disclosed. The membranes include a polymeric matrix and a particulate material immobilized within the matrix. The membranes may find particular application in methods and apparatus for removing organic compounds from a biological fluid as part of a pathogen inactivation treatment.

Methods and devices are provided for reducing the concentration of low molecular weight compounds in a biological composition, while substantially maintaining a desired biological activity of the biological composition. The device comprises highly porous adsorbent particles, and the adsorbent particles are immobilized by an inert matrix. The matrix containing the particles is contained in a housing, and the particles range in diameter from about 1 μm to about 200 μm. The matrix can be fibrous, and the particles can have a surface area greater than 750 m²/g and a pore diameter between about 25 and 800 Å. The device can be used to adsorb and remove a pathogen-inactivating compound that is a nucleic acid-binding compound such as psoralen, an acridine derivative or a dye from a biological composition such as a blood product.

Membranes and methods for making membranes are disclosed. The membranes include a polymeric matrix and a particulate material immobilized within the matrix. The membranes may find particular application in methods and apparatus for removing organic compounds from a biological fluid as part of a pathogen inactivation treatment.

The invention provides a method to reduce the rate of tumor metastasis and tumor recurrence after surgery and chemotherapy and radiotherapy by removing circulating tumor cells (CTC) in the blood after surgery and chemotherapy and radiotherapy by means of specificity, thereby improving the survival rate of cancer patients. The invention provides a method and a system for removing tumor cells. Patients ' blood is guided out to pass through a container, an antibody or a ligand capable of combining with the specificity of the tumor cells is fixed on a solid-phase carrier in the container, whne the patients ' blood passes through the container, the tumor cells can be absorbed by the specificity to be unable to flow back to patients ' blood, and then the tumor cells are removed from the blood to reduce the recidivation of tumor patients and to prolong their survival rate. The removed tumor cells can be washed out from the solid-phase carrier for counting. The invention further provides a method to remove pathogen from blood. Blood is withdrawn from a patient and its plasma and cellular components are separated by means of a plasma separator under the effect of a blood pump, the plasma portion inactivates the pathogen in the blood via a pathogen inactivating device, flows back to extracorporeal circulation passage to merge with the cellular components and then is returned to the patient. The method adopts a physical means, so that side effects can be reduced. The device is simple in structure and can be connected with other blood purification devices.

The systems and methods for pathogen reduction in donor blood operates by exposure of blood to UVC irradiation. Unwanted wavelengths of light, mostly in the infrared spectra, may be precluded from reaching blood by providing a layer of IR-absorbing fluid positioned between blood and the source of UV irradiation, whereby minimizing energy absorption and heating of blood. Some embodiments further disclose a system configured to utilize the same IR-absorbing fluid to actively cool blood by flowing along the flow path thereof.

This invention is directed toward a method of pathogen inactivating whole blood. The steps include collecting whole blood from a donor into a bag; illuminating the whole blood with light at a sufficient energy so that an alloxazine photosensitizer present in the whole blood may be photolyzed to inactivate any pathogens which may be present in the whole blood; and storing the pathogen inactivated whole blood. The invention also includes a method of separating the pathogen inactivated whole blood into components.

Methods are provided for quenching undesired side reactions of pathogen inactivating compounds in biological materials comprising red blood cells. In a particular embodiment, methods are provided for quenching undesired side reactions of a pathogen inactivating compound that includes a functional group which is, or which is capable of forming, an electrophilic group. In this embodiment, the material is treated with the pathogen inactivating compound and a quencher, wherein the quencher comprises a nucleophilic functional group that is capable of covalently reacting with the electrophilic group. The electrophilic group on the pathogen inactivating compound is preferably a non-radical cationic group. In one embodiment, the pathogen inactivating compound includes a nucleic acid binding ligand and a mustard group, wherein the mustard group is capable of reacting in situ to form the electrophilic group. Preferred quenchers are thiols, such as glutathione. The methods permit inhibition of the modification of red blood cells in red blood cell containing materials during pathogen inactivation.

Methods are provided for improved quenching of undesired side reactions upon treating a red blood cell composition with a pathogen inactivating compound comprising a nucleic acid binding ligand and a functional group which is, or which is capable of forming, an electrophilic group. In some embodiments, the improved methods use a suitably high concentration of quencher that comprises a nucleophilic functional group that is capable of covalently reacting with the electrophilic group, wherein the treatment occurs within a desired pH range to provide sufficient quenching. Preferred quenchers for use in some of the methods include thiols, such as glutathione, which have been suitably neutralized such that addition to a red blood cell composition results in the desired concentration of quencher at a desirable pH range of 6.8 to 8.5.

The present invention relates to methods for improving therapeutic activity of NK cell, such as their cytotoxic/cytolytic activity, to be used in immunotherapy, by gene editing. In particular, these methods comprise a step of reduction or inactivation of gene expression using specific endonuclease such as TAL-nuclease, CRISPR or Argonaute. An additional genetic modification can be performed by (over)expressing at least one gene involved in N K function. The present invention encompasses also engineered NK cell, pharmaceutical composition containing the same.

The invention discloses a two-dimensional ultrathin nanosheet graphite phase carbon nitride material rich in nanopores, and a preparation method and applications thereof, and belongs to the technicalfield of nanometer functional material preparation, solar energy utilization, and environment protection. The two-dimensional ultrathin nanosheet graphite phase carbon nitride material rich in nanopores is prepared through oriented thermal polymerization combined two-step thermal processing technology; more specifically, a liquid phase template agent is adopted to control the thickness of a nanosheet g-C3N4 material, two-step thermal processing technology parameter design is adopted for forming of nanopores on nanosheets; the forming of the nanopores is capable of introducing more active sites, so that the nanosheet g-C3N4 material obtained at last possesses appropriate light absorption characteristic, and relatively high photo-induced electron and cavity separation efficiency, a defect ofblock-shaped g-C3N4 material that photocatalytic efficiency is low is improved, and the two-dimensional ultrathin nanosheet graphite phase carbon nitride material rich in nanopores can be directly used for organic matter decomposition, microbial pathogen inactivation, and photocatalytic reduction CO2 to produce organic matters under sunlight.

The invention provides a preserving fluid for biological sample nucleic acid detection and an application thereof. The preserving fluid is composed of a nuclease inhibitor, a surfactant, a chelating agent and a buffer solution. The preserving fluid is mixed with a solid sample or a liquid sample to denature proteins, inactivate pathogens, and inactivate DNA and RNA nuclease. The pathogens are inactivated, so the safety of a potential high-infectivity clinical sample is greatly improved, and good protection is formed for surrounding personnel and downstream operating personnel of the sample; the DNA and RNA nuclease is inactivated, so that the content and integrity of DNA and RNA in the sample are kept in a sampling state to the maximum extent, and the strict requirements on the aspects oftemperature, time and the like of clinical sample transportation and storage are reduced. The preserving fluid can be used for clinical high-infectivity nucleic acid detection of biological samples, and the biological samples comprise throat swabs, body fluids, lavage fluids, whole blood, whole blood cells, serum or plasma.

The present invention provides improved methods for treating red blood cell compositions with a pathogen-inactivating compound under conditions which provide suitable pathogen inactivation while maintaining cell vitality. Also provided methods of reducing dehydration in red blood cells, as well as treated red blood cell compositions.

The disclosure relates to uses, methods and compositions for the inactivation of pathogens in biological compositions, using a glycol as a pathogen inactivating agent.

Provided herein are improved processes for preparing and treating platelet products. The methods are useful in the efficient preparation of platelet products with desirable characteristics, including pathogen inactivated platelet products.

A method for reducing hemolysis and microparticle formation during storage of pathogen reduced blood. Oxygen reduced blood compositions comprising SAGM and riboflavin having reduced hemolysis. Oxygen reduced blood compositions comprising SAGM and riboflavin having reduced microparticles. Oxygen and pathogen reduced blood compositions comprising CPAD and riboflavin having reduced hemolysis. Oxygen and pathogen reduced blood compositions comprising SAGM and riboflavin having reduced microparticles.

A lighting fixture is disclosed with effective disinfection properties against bacteria, fungi, and viruses. The fixture includes a fan to continuously draw air into the light fixture. The air drawn in is irradiated with UV radiation within the fixture, such as is provided from UV LED chips. The relatively small volume of the light fixture allows the flux or energy density of the UV radiation to be made more intense. After the air is sterilized, it can be put back into the room or building in which the fixture is placed. The white light provided by white light LEDs in the fixture provides illumination, and can further provide significant emission peaks at 405 nm and 470 nm which is also useful to pathogen inactivation.

A sample of produce wash water containing an antimicrobial sanitizer fluid, and a reference pathogen fluid are both injected into a pathogen inactivation region of a micro-fluidic mixer. The produce wash water (i.e. sanitizer fluid/pathogen fluid mix) is directed through mixer elements in the pathogen inactivation region of the micro-fluidic mixer. In the sanitizer deactivation region, a sanitizer deactivation solution is added to the sanitizer fluid/pathogen fluid mix to produce a deactivated solution. The deactivated solution is evaluated for the presence of the pathogen and the characteristics of the sanitizer. In the preferred embodiment, the sanitizer comprises chlorine and the pathogen comprises E. coli bacteria.